Vnitr Lek 2008, 54(5):511-517

Diabetes, dyslipidaemia and kidney diseases

R. Češka^1,*, V. Tesař²

¹ III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

² Nefrologická klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Vladimír Tesař, DrSc.

Dyslipidemia (DLP) is the most significant risk factor for cardiovascular diseases (CVD). Similarly, the relevance of diabetes mellitus (DM) as a CVD risk indicator is so high that it is attributed the same significance as the secondary prevention of CVD in different systems of global cardiovascular risk assessment. Most recently, also kidney disorders have been increasingly referred to as a risk factor for the manifestation of CVD. According to some guidelines, patients with kidney disorders are at the same risk as the patients with manifest IHD (or another manifestation of atherosclerosis), and patients with DM. This paper does not pretend to resolve the complex relationship between DLP, DM and nephropathy. Its sole objective is to bring attention to the fact that it is a relevant and significant issue which is gradually becoming a central point of attention. The first part of the article deals primarily with diabetic DLP and the different options for its management. The second part deals with the role of DLP in kidney disorders, the risk it represents and the options for its management, as well as with the results of the first intervention studies. The studies focused on the effect of hypolipidemic therapy on CV risk of patients on the one hand and, on the other hand, on the way hypolipidemic drugs contribute to the improvement or sustaining of renal functions, or on their influence on renal disease markers.

Keywords: dyslipidaemia; renal insufficiency; nephropathy; albuminuria; statins; fibrates; ezetimibe; hypolipidemic drugs

Received: April 14, 2008; Published: May 1, 2008  Show citation